Latest Ratios: P/E Ratio -0.5x · EV/EBITDA N/A · ROE -139.9%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $27M | $30M | $41M | — | — | — | — |
| Enterprise Value | $24M | $26M | $28M | — | — | — | — |
| P/E Ratio → | -0.50 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 1.46 | 1.74 | 0.76 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -139.9% | -139.9% | -205.2% | -0.1% | -0.1% | -0.1% | -0.2% |
| ROA | -106.8% | -106.8% | -71.8% | -0.0% | -0.1% | -0.1% | -0.1% |
| ROIC | -59.6% | -59.6% | -313.6% | -0.8% | -0.1% | -0.1% | — |
| ROCE | -53.8% | -53.8% | -78.9% | -0.0% | -0.1% | -0.1% | -0.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.01 | 0.00 | 0.00 | 0.03 |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.19 | -0.24 | -2.51 | -0.28 | -0.08 | -0.55 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — |
Net cash position: cash ($3M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.70 | 0.70 | 2.38 | 4.17 | 6.46 | 10.69 | 4.12 |
| Quick Ratio | 0.70 | 0.70 | 2.38 | 4.17 | 6.46 | 10.69 | 4.12 |
| Cash Ratio | 0.52 | 0.52 | 2.24 | 3.95 | 6.28 | 10.19 | 3.49 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $25M | $18M | $5M | $5M | $4M | $17M |
Imminent liquidity shortfall
As reported in financial statements, RNTX trades at a price-to-book ratio of 1.46, a valuation that appears to reflect the market's skepticism regarding the company's ability to monetize its stapled peptide platform before its remaining cash reserves are fully exhausted by ongoing clinical development costs.
The lack of meaningful revenue renders traditional P/E or EV/EBITDA metrics non-functional, forcing investors to view the company as a speculative option on clinical trial outcomes. This valuation suggests that the market is pricing in a high probability of further dilution or a potential restructuring event rather than long-term earnings growth.
Based on the company's reported figures, ROIC has deteriorated to -30.4% as of 2026Q1, illustrating a consistent trend of value destruction as the firm continues to deploy capital into high-risk clinical programs that have yet to demonstrate a path toward positive economic returns or sustainable margin generation.
The persistent negative returns on invested capital indicate that the company's research-heavy model is failing to generate sufficient value to offset the costs of its clinical pipeline. Investors should monitor whether management can pivot toward a more capital-efficient licensing model, as the current trajectory suggests a structural inability to compound capital.
According to recent SEC filings, RNTX's current ratio has collapsed to 0.40 in 2026Q1, a significant decline from historical levels that highlights the company's severe inability to cover its short-term liabilities with existing liquid assets as it approaches a potential funding cliff.
This liquidity profile suggests that the firm is highly vulnerable to even minor operational disruptions or delays in clinical milestones. The rapid compression of the current ratio warrants close investigation, as it implies that the company may be forced to seek emergency financing under unfavorable terms to maintain its going-concern status.
As evidenced by the company's financial records, the price-to-book ratio is frequently misapplied to RNTX, as it obscures the reality that the firm's assets are primarily intangible clinical-stage intellectual property rather than tangible resources that could be liquidated to satisfy creditors in a distress scenario.
Investors should instead focus on the cash burn rate and the probability-adjusted net present value of the lead asset, ALRN-6924. Relying on book value provides a false sense of security, as it fails to account for the high likelihood of future impairment charges related to the company's capitalized research and development costs.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RNTX stock.
Rein Therapeutics Inc.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
Rein Therapeutics Inc.'s return on equity (ROE) is -139.9%. The historical average is -57.6%.
Based on historical data, Rein Therapeutics Inc. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.